Enzymatic	O
biosynthesis	O
of	O
novel	O
neobavaisoflavone	B:C2934343
glucosides	I:C2934343
via	O
Bacillus	O
UDP	O
-	O
glycosyltransferase	O
.	O

Enzymatic	O
biosynthesis	O
of	O
novel	O
neobavaisoflavone	O
glucosides	I:C2934343
via	O
Bacillus	B:C0004587
UDP	O
-	O
glycosyltransferase	O
.	O

Enzymatic	O
biosynthesis	O
of	O
novel	O
neobavaisoflavone	O
glucosides	I:C2934343
via	O
Bacillus	O
UDP	B:C0041986
-	O
glycosyltransferase	O
.	O

Enzymatic	O
biosynthesis	O
of	O
novel	O
neobavaisoflavone	O
glucosides	I:C2934343
via	O
Bacillus	O
UDP	O
-	O
glycosyltransferase	B:C0085249
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	B:C3890228
modifications	I:C3890228
of	O
of	O
neobavaisoflavone	O
(	O
neobavaisoflavone	O
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	O
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	O
its	O
water	O
-	O
solubility	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	O
modifications	I:C3890228
of	O
of	O
neobavaisoflavone	B:C2934343
(	O
neobavaisoflavone	O
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	O
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	O
its	O
water	O
-	O
solubility	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	O
modifications	I:C3890228
of	O
of	O
neobavaisoflavone	O
(	O
neobavaisoflavone	B:C2934343
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	O
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	O
its	O
water	O
-	O
solubility	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	O
modifications	I:C3890228
of	O
of	O
neobavaisoflavone	O
(	O
neobavaisoflavone	O
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	B:C0014442
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	O
its	O
water	O
-	O
solubility	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	O
modifications	I:C3890228
of	O
of	O
neobavaisoflavone	O
(	O
neobavaisoflavone	O
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	O
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	B:C0184511
its	O
water	O
-	O
solubility	O
.	O

Two	O
novel	O
glucosides	B:C0017765
of	O
neobavaisoflavone	O
were	O
obtained	O
from	O
an	O
enzymatic	O
glycosylation	O
by	O
UDP	O
-	O
glycosyltransferase	O
.	O

Two	O
novel	O
glucosides	O
of	O
neobavaisoflavone	B:C2934343
were	O
obtained	O
from	O
an	O
enzymatic	O
glycosylation	O
by	O
UDP	O
-	O
glycosyltransferase	O
.	O

Two	O
novel	O
glucosides	O
of	O
neobavaisoflavone	O
were	O
obtained	O
from	O
an	O
enzymatic	B:C0014442
glycosylation	O
by	O
UDP	O
-	O
glycosyltransferase	O
.	O

Two	O
novel	O
glucosides	O
of	O
neobavaisoflavone	O
were	O
obtained	O
from	O
an	O
enzymatic	O
glycosylation	O
by	O
UDP	B:C0041986
-	O
glycosyltransferase	O
.	O

Two	O
novel	O
glucosides	O
of	O
neobavaisoflavone	O
were	O
obtained	O
from	O
an	O
enzymatic	O
glycosylation	O
by	O
UDP	O
-	O
glycosyltransferase	B:C0085249
.	O

The	O
glycosylated	B:C2934343
products	I:C2934343
were	O
elucidated	O
by	O
LC	O
-	I:C0872318
MS	I:C0872318
,	O
HR	O
-	I:C0596495
ESI	I:C0596495
-MS	I:C0596495
,	O
and	O
NMR	O
analysis	O
.	O

The	O
glycosylated	O
products	I:C2934343
were	O
elucidated	O
by	O
LC	B:C0872318
-	I:C0872318
MS	I:C0872318
,	O
HR	O
-	I:C0596495
ESI	I:C0596495
-MS	I:C0596495
,	O
and	O
NMR	O
analysis	O
.	O

The	O
glycosylated	O
products	I:C2934343
were	O
elucidated	O
by	O
LC	O
-	I:C0872318
MS	I:C0872318
,	O
HR	B:C0596495
-	I:C0596495
ESI	I:C0596495
-MS	I:C0596495
,	O
and	O
NMR	O
analysis	O
.	O

The	O
HPLC	B:C0008562
peaks	O
were	O
integrated	O
and	O
the	O
concentrations	O
in	O
sample	O
solutions	O
were	O
calculated	O
.	O

The	O
MTT	B:C0201596
assay	I:C0201596
was	O
used	O
to	O
detect	O
the	O
cytotoxic	O
activity	I:C0596402
of	O
compounds	O
in	O
cancer	O
cell	I:C0085983
lines	I:C0085983
.	O

The	O
MTT	O
assay	I:C0201596
was	O
used	O
to	O
detect	O
the	O
cytotoxic	B:C0596402
activity	I:C0596402
of	O
compounds	O
in	O
cancer	O
cell	I:C0085983
lines	I:C0085983
.	O

The	O
MTT	O
assay	I:C0201596
was	O
used	O
to	O
detect	O
the	O
cytotoxic	O
activity	I:C0596402
of	O
compounds	O
in	O
cancer	B:C0085983
cell	I:C0085983
lines	I:C0085983
.	O

Based	O
on	O
the	O
spectroscopic	O
analyses	B:C0936012
,	O
the	O
two	O
novel	O
glucosides	O
were	O
identified	O
as	O
neobavaisoflavone	O
-	I:C2934343
4'-	I:C2934343
O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
1	I:C2934343
)	I:C2934343
and	O
neobavaisoflavone	O
-	I:C2934343
4	I:C2934343
'	I:C2934343
,	I:C2934343
7	I:C2934343
-	I:C2934343
di-O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
2	I:C2934343
)	I:C2934343
.	O

Based	O
on	O
the	O
spectroscopic	O
analyses	O
,	O
the	O
two	O
novel	O
glucosides	B:C0017765
were	O
identified	O
as	O
neobavaisoflavone	O
-	I:C2934343
4'-	I:C2934343
O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
1	I:C2934343
)	I:C2934343
and	O
neobavaisoflavone	O
-	I:C2934343
4	I:C2934343
'	I:C2934343
,	I:C2934343
7	I:C2934343
-	I:C2934343
di-O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
2	I:C2934343
)	I:C2934343
.	O

Based	O
on	O
the	O
spectroscopic	O
analyses	O
,	O
the	O
two	O
novel	O
glucosides	O
were	O
identified	O
as	O
neobavaisoflavone	B:C2934343
-	I:C2934343
4'-	I:C2934343
O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
1	I:C2934343
)	I:C2934343
and	O
neobavaisoflavone	O
-	I:C2934343
4	I:C2934343
'	I:C2934343
,	I:C2934343
7	I:C2934343
-	I:C2934343
di-O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
2	I:C2934343
)	I:C2934343
.	O

Based	O
on	O
the	O
spectroscopic	O
analyses	O
,	O
the	O
two	O
novel	O
glucosides	O
were	O
identified	O
as	O
neobavaisoflavone	O
-	I:C2934343
4'-	I:C2934343
O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
1	I:C2934343
)	I:C2934343
and	O
neobavaisoflavone	B:C2934343
-	I:C2934343
4	I:C2934343
'	I:C2934343
,	I:C2934343
7	I:C2934343
-	I:C2934343
di-O-β-D-glucopyranoside	I:C2934343
(	I:C2934343
2	I:C2934343
)	I:C2934343
.	O

Additionally	O
,	O
the	O
water	O
-	O
solubilities	O
of	O
compounds	B:C2934343
1	I:C2934343
and	I:C2934343
2	I:C2934343
were	O
approximately	O
175.1	O
-	O
and	O
4	O
031.9	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
substrate	O
,	O
respectively	O
.	O

Among	O
the	O
test	O
compounds	O
,	O
only	O
neobavaisoflavone	B:C2934343
exhibited	O
weak	O
cytotoxicity	O
against	O
four	O
human	O
cancer	I:C0085983
cell	I:C0085983
lines	I:C0085983
,	O
with	O
IC50	O
values	O
ranging	O
from	O
63.47	O
to	O
72.81	O
µmol·L	O
(	O
-	O
1	O
)	O
.	O

Among	O
the	O
test	O
compounds	O
,	O
only	O
neobavaisoflavone	O
exhibited	O
weak	O
cytotoxicity	B:C0596402
against	O
four	O
human	O
cancer	I:C0085983
cell	I:C0085983
lines	I:C0085983
,	O
with	O
IC50	O
values	O
ranging	O
from	O
63.47	O
to	O
72.81	O
µmol·L	O
(	O
-	O
1	O
)	O
.	O

Among	O
the	O
test	O
compounds	O
,	O
only	O
neobavaisoflavone	O
exhibited	O
weak	O
cytotoxicity	O
against	O
four	O
human	B:C0085983
cancer	I:C0085983
cell	I:C0085983
lines	I:C0085983
,	O
with	O
IC50	O
values	O
ranging	O
from	O
63.47	O
to	O
72.81	O
µmol·L	O
(	O
-	O
1	O
)	O
.	O

These	O
results	O
suggest	O
that	O
in	O
vitro	O
enzymatic	B:C0014442
glycosylation	O
is	O
a	O
powerful	O
approach	O
to	O
structural	O
modification	I:C0581602
,	O
improving	O
water	O
-	O
solubility	O
.	O

These	O
results	O
suggest	O
that	O
in	O
vitro	O
enzymatic	O
glycosylation	O
is	O
a	O
powerful	O
approach	O
to	O
structural	B:C0581602
modification	I:C0581602
,	O
improving	O
water	O
-	O
solubility	O
.	O

